Graziela Zibetti Dal Molin

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors

Graziela Zibetti Dal Molin, Shannon N. Westin, Pavlos Msaouel et al. · International Journal of Gynecological Cancer · 2019 · 46 citations

Medicine, Nuclear Medicine, Pharmacotherapy +17

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial

Robert L. Coleman, Katelyn F. Handley, Robert A. Burger et al. · Gynecologic Oncology · 2020 · 42 citations

Medicine, Oncology, Pharmacology +14

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

Graziela Zibetti Dal Molin, Carina Meira Abrahão, Robert L. Coleman et al. · Gynecologic Oncology Research and Practice · 2018 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Anca Chelariu-Raicu, Alpa M. Nick, Renata R. Urban et al. · Gynecologic Oncology · 2020 · 19 citations

Medicine, Oncology, Pharmacology +17